Get the Stockscreener App
2.50
0.00%
0.00
After Hours:
2.49
-0.010
-0.40%
Boundless Bio Inc stock is traded at $2.50, with a volume of 116.62K.
It is up +0.00% in the last 24 hours and up +76.06% over the past month.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
See More
Previous Close:
$2.50
Open:
$2.47
24h Volume:
116.62K
Relative Volume:
0.09
Market Cap:
$56.19M
Revenue:
-
Net Income/Loss:
$-55.99M
P/E Ratio:
-0.9995
EPS:
-2.5013
Net Cash Flow:
$-47.60M
1W Performance:
+0.00%
1M Performance:
+76.06%
6M Performance:
+95.31%
1Y Performance:
+129.36%
1-Day Range:
$2.44
$2.50
1-Week Range:
$2.44
$2.60
52-Week Range:
$0.9612
$2.79
Boundless Bio Inc Stock (BOLD) Company Profile
Name
Boundless Bio Inc
Sector
Industry
Phone
(858) 766-9912
Address
10955 ALEXANDRIA WAY, SAN DIEGO
Compare BOLD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
2.50 | 56.19M | 0 | -55.99M | -47.60M | -2.5013 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-13-24 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-22-24 | Initiated | Guggenheim | Buy |
| Apr-22-24 | Initiated | Leerink Partners | Outperform |
| Apr-22-24 | Initiated | Piper Sandler | Overweight |
View All
Boundless Bio Inc Stock (BOLD) Latest News
Boundless Bio to merge with Serapha Bio in reverse merger; shares surge - MSN
Boundless Bio ten percent owner Kristina Burow sells $39,840 in stock - Investing.com
Arch venture funds sell $39,840 in Boundless Bio stock - Investing.com
Form 4 Boundless Bio Inc For: 6 July By Investing.com - Investing.com Canada
ARCH funds, insiders trade 16,000 Boundless Bio (BOLD) shares - Stock Titan
16K Boundless Bio (BOLD) shares sold by ARCH funds post-exercise - Stock Titan
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Boundless Bio Inc - GuruFocus
Major Investor Doubles Down on Boundless Bio With Bold New Stock Purchase - TipRanks
Kevin Tang buys $268,880 of Boundless Bio (NASDAQ:BOLD) shares - Investing.com
Form 4 Boundless Bio Inc For: 2 July By Investing.com - Investing.com UK
Boundless Bio (BOLD) major holder buys 107,463 Common shares - Stock Titan
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ACA, APGE, BOLD, and GBCS - Sahm
Major Investor Makes Bold Move on Boundless Bio Shares - TipRanks
Tang Capital Management acquires $714,768 of Boundless Bio stock - Investing.com
Tang Capital Management acquires $714,768 of Boundless Bio stock By Investing.com - Investing.com Nigeria
Form 4 Boundless Bio Inc For: 29 June By Investing.com - Investing.com India
Tang-linked entities report 11.3% stake in Boundless Bio (NASDAQ: BOLD) - Stock Titan
Tang Capital-affiliated funds boost Boundless Bio (BOLD) stake with 286K-share buy - Stock Titan
Tang Capital entities disclose 2.25M Boundless Bio (BOLD) shares in Form 3 filing - Stock Titan
Enterprise value to revenue forward of Boundless Bio, Inc. – NASDAQ:BOLD - TradingView
Enterprise value to EBITDA forward of Boundless Bio, Inc. – NASDAQ:BOLD - TradingView
Price to sales forward of Boundless Bio, Inc. – NASDAQ:BOLD - TradingView
Boundless Bio Inc. Actuals & Estimates (NASDAQ:BOLD) - TradingView
BOLD Forecast — Price Target — Prediction for 2027 - TradingView
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? - TradingView
Crude Oil Down Over 1%; US Manufacturing PMI Surges In June - Sahm
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Sahm
Dow Falls Over 300 Points; Korn Ferry Earnings Top Views - Sahm
NewCo Serapha taking path to NASDAQ via merger with Boundless: Deals Report - biocentury.com
$Boundless Bio (BOLD.US)$ - Moomoo
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD) - PR Newswire
Serapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from China - Fierce Biotech
Form 8K Boundless Bio Inc For: 23 June By Investing.com - Investing.com South Africa
Boundless Bio and Serapha Bio to merge - The Pharma Letter
BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
Boundless Bio's reverse merger; CARsgen wins first solid tumor approval for CAR-T - Endpoints News
Boundless Bio Inc. (BOLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
The market is filled with gapping stocks in Tuesday's session. - ChartMill
Boundless Bio to Merge with Serapha Bio, Restructure Operations - TipRanks
BOLD Stock Pops As Traders Target Volatile Bounce - StocksToTrade
BOLD: All-stock merger creates a focused gene editing company targeting AATD with strong financial runway - TradingView
BOLD: All-stock merger creates a gene-editing leader targeting AATD, with Boundless shareholders receiving a cash dividend - TradingView
US market outlook: Semiconductors and large-cap stocks decline amid concerns over US rate hikes and rising procurement costs; SoFi acquires Composer to bolster AI-driven trading; Boundless Bio shares surge on merger announcement with Seraffa - Moomoo
BOLD Stock Grinds Sideways As Traders Eye Cash Runway - timothysykes.com
Boundless Bio stock surges on Serapha Bio merger agreement By Investing.com - Investing.com Australia
Boundless Bio stock surges on Serapha Bio merger agreement - Investing.com
Boundless Bio (BOLD) to merge with Serapha after $230M+ financings; 75% workforce cut - Stock Titan
Serapha Bio to take control of Boundless Bio (NASDAQ: BOLD) in cash-dividend merger - Stock Titan
What's going on in today's pre-market session - ChartMill
Boundless Bio Agrees To Merge With Serapha Bio - Finimize
Boundless Bio Inc Stock (BOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Boundless Bio Inc Stock (BOLD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CRANDELL KEITH | 10% Owner |
Jul 01 '26 |
Sale |
2.49 |
16,000 |
39,840 |
0 |
| ARCH Venture Fund IX, L.P. | 10% Owner |
Jul 01 '26 |
Option Exercise |
1.03 |
16,000 |
16,480 |
16,000 |
| ARCH Venture Fund IX, L.P. | 10% Owner |
Jul 01 '26 |
Sale |
2.49 |
16,000 |
39,840 |
0 |
| TANG KEVIN | 10% Owner |
Jul 01 '26 |
Buy |
2.49 |
71,612 |
178,314 |
2,631,487 |
| TANG KEVIN | 10% Owner |
Jun 30 '26 |
Buy |
2.54 |
26,030 |
66,112 |
2,559,875 |
| TANG KEVIN | 10% Owner |
Jul 02 '26 |
Buy |
2.49 |
9,821 |
24,454 |
2,641,308 |
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):